We had previously reported the efficacy of erlotinib after gefitinib failure in Asian patients
with non-small cell lung cancer (NSCLC). 1 Other authors have seen responses with a …

Background Third-generation tyrosine kinase inhibitors of the epidermal growth factor
receptor (EGFR-TKIs) have proved efficacious in treating non-small cell lung cancer …

Purpose Recent studies have demonstrated that erlotinib therapy may be considered an
option for patients with advanced non-small-cell lung cancer who experienced disease …

Discussion Several trials have investigated the use of erlotinib after gefitinib failure in
relapsed NSCLC. 2 A longer progression-free survival was predicted by use of cytotoxic …

目的: 观察吉非替尼在化疗失败的晚期肺腺癌中的疗效, 生存时间及影响因素. 方法: 收集21
例初始化疗失败的转移性肺腺癌, 应用吉非替尼250mg 口服, 每日1 次, 直至出现有客观证据的 …

目的观察吉非替尼常规剂量耐药的晚期非小细胞肺癌患者加量应用吉非替尼或更换厄洛替尼的
疗效. 方法选择2007 年6 月—2012 年5 月大连医科大学附属第一医院收治的40 …

Background: The optimal strategy was not established for patients who initially responded to
gefitinib although re‐administration of epidermal growth factor receptor (EGFR) tyrosine …

目的: 介绍表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI) 耐药后治疗方案的选择依据及优势.
方法: 根据近年来的相关文献和指南进行综述, 对EGFR-TKI 耐药后治疗方案的适用人群及临床 …

Moreover, among the 104 patients who have obtained a disease control with gefitinib, 42
(40.4%) experienced a disease control (PR or SD) also from erlotinib treatment. Preclinical …